Repetitive Transcranial Magnetic Stimulation as Treatment for Acute Suicidality in Adult Patients
NCT ID: NCT02693743
Last Updated: 2021-05-18
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
NA
Total Enrollment
1 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-05-22
Study Completion Date
2019-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Suicide was responsible for almost 40,000 deaths in 2011 in America. It is still singularly difficult to predict who is going to commit suicide and how to establish adequate interventions. Growing evidence supports the view that suicide is associated with poor decision making. Suicide is hypothesized to be triggered by stressful situations that create overwhelming psychological pain in an individual who chooses to terminate his/her own life, disregarding all future consequences. We have previously demonstrated rewarding impulsive choice common to both recent suicide attempters and suicidal depressed patients (1). Consistent with these findings, we hypothesize that high frequency repetitive transcranial magnetic stimulation (rTMS) of the left prefrontal cortex will improve impulsive response tendencies as measured by the delay discounting procedure, and this in turn will be associated with a faster resolution of suicidal ideation. To these effects we will be using a randomized control trial of rTMS in adult inpatients at the Psychiatric Research Institute (PRI) hospitalized for acute suicidality. At the conclusion of these studies, we will have tested the value of decision making in the development of suicide ideation and behavior, as well as piloted the use of rTMS in the treatment of these patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transcranial Magnetic Stimulation (TMS) for Suicidal Ideation
NCT01212848
Depressive Episode
Posttraumatic Stress Disorder
Traumatic Brain Injury
UNKNOWN
PHASE3
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
NCT05489042
Substance Abuse
Suicide
Depression
RECRUITING
NA
Rapid Acting TMS for Suicide Ideation in Depression
NCT05100004
Depressive Disorder, Major
Suicide
WITHDRAWN
NA
TMS for Suicidal Crisis in Active Duty SMs
NCT03014362
Suicide
Suicidal Ideation
Suicidal Impulses
+3 more
COMPLETED
NA
Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms
NCT02611206
Treatment Resistant Depression
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The proposed study seeks to improve the prevention of suicide by advancing our understanding of the neurobiology of suicide by using a randomized control trial of repetitive transcranial magnetic stimulation (rTMS) as a hypothesis driven intervention for acute suicidality. In 2010 suicide was responsible for more than 38,364 deaths in the United States and 447 in the state of Arkansas (CDC, 2012). Suicide represents the 10th leading cause of death in this country, and claims more deaths than chronic liver disease, hypertension, Parkinson's disease or homicide. Furthermore, suicide consequences extend beyond the termination of an individual's life to impact those that are left behind. These statistics are far more alarming because they are believed to be underestimates, with substantial numbers of suicides and suicide attempts undetected or misclassified. The high and rising prevalence of suicide is complicated by the clinical challenge of identifying those patients at highest risk for suicide. A variety of biological, psychological and social risk factors for suicide have been identified. However, we currently lack reliable predictors of suicide risk and must rely heavily upon self-report and clinical judgment. Thus, it remains singularly difficult to predict who is going to commit suicide. Therefore, there is an urgent unmet need to develop effective early detection methods and treatments for high-risk populations.
Suicide has been described as "a permanent solution to a temporary problem" (Buchwald, 2006), reflecting the view that suicide is the result of poor decision making. The strongest biological finding in suicide research is the association with reduced serotonergic neurotransmission, particularly within the ventromedial prefrontal cortex (VMPFC) (Mann, 2003). This deficit in serotonergic neurotransmission is thought to impair cognition, predisposing patients to become more impulsive, rigid in their thinking, and poorer decision makers. Decisions during depressed states are tainted by negative affect and distorted negative cognitions (Martin-Soelch, 2009). However, suicide has been associated with cognitive impairments that go beyond those of depression. Asymptomatic patients with a history of suicide attempts exhibit significant cognitive deficits suggestive of generalized prefrontal cortex (PFC) dysfunction (Raust et al, 2007; Westheide et al, 2008), and corollary disruptions in risk assessment (Martino et al, 2010). Poor inhibition is found in suicide attempters when compared with patients with only suicidal ideation (Burton et al, 2011), and greater cognitive impairments are found in depressed patients with suicidal ideation compared to those without it (Dombrovski et al, 2010). It is possible that cognitive deficits may be specific to suicidal behavior rather than to any comorbid or specific psychiatric diagnosis because this observation holds true for suicidal patients with depression, bipolar disorder, and even temporal lobe epilepsy. However, most of these studies were performed in symptom-free patients, often months or years after the presence of suicidal ideation or behavior. In a previous report (Cáceda et al, 2014) we demonstrated that inability to delay gratification (choosing smaller immediate rewards over larger delayed rewards) is shared by both recent suicide attempters and depressed patients with suicidal ideation. On a follow up assessment, 5-10 days after the suicide attempt, reduction of suicidal ideation and intent was correlated with decreased symptoms of depression and recovery of delayed gratification impairments (Cáceda et al, 2014). These data are congruent with the hypothesis that stressful situations in combination with a biological and psychological predisposition may create a critical climate of overwhelming psychological pain in an individual who chooses an impulsive escapist strategy to terminate his/her own life discounting all future outcomes (Vohs et al, 2002). However, the underlying neural mechanisms remain unknown and therefore not amenable to therapeutic interventions.
TMS is a noninvasive method to cause depolarization or hyperpolarization in the neurons in the brain using electromagnetic induction to induce weak electric currents using a rapidly changing magnetic field. TMS is a novel intervention developed in the field of neurology that has been used in the treatment of patients suffering from migraine, stroke, Parkinson's disease, tinnitus and depression. In healthy subjects, high frequency rTMS over the left DLPFC has been shown to alter impulsive choice behavior (to decrease delay discounting) in healthy individuals and in smokers (Sheffer et al, 2013). On the other hand, a trial of TMS by one of the leaders in the field has shown it to be safe and well tolerated in recent suicide attempters suffering from depression with comorbid post-traumatic stress disorder and traumatic brain injury (George et al, 2014).
Dr. Mennemeier, the director of the Transcranial Magnetic Stimulation Laboratory in the Center for Translational Neuroscience has been using repetitive transcranial magnetic stimulation (rTMS) to understand and treat phantom sound perception in subjects with tinnitus and to examine risky choices and impulsive behaviors using delay discounting in smokers. We propose to replicate a randomized controlled trial of rTMS over 3 days in a sample of well characterized acutely suicidal inpatients.
Our overall hypothesis is that 10 Hertz rTMS of the left dorsolateral prefrontal cortex (DLPFC) will correct impulsive choice behavior deficits found in acutely suicidal patients that in turn will translate into faster resolution of acute suicidal ideation. The current proposal will expand our understanding of the neurobiology of suicidal behavior by examining a potential neurocognitive mechanism of acute suicidality and test the value of rTMS as intervention for acute suicidal behavior. The current proposal will utilize behavioral assessments and rTMS in a randomized controlled trial in a group of adult patients hospitalized: a) following a recent suicide attempt with persistent suicidal ideation, or b) for severe suicidal ideation (n=20). Specifically, we propose:
Specific Aim 1. Determine the safety of repetitive transcranial magnetic stimulation (rTMS) in depressed patients with severe suicidal ideation.
Hypothesis 1: Given studies of rTMS for clinical depression, the investigators predict that rTMS in patients with severe suicidal ideation will be well tolerated and not associated with significant side effects.
Specific Aim 2. Determine the effect of rTMS on delay discounting on depressed patients with severe suicidal ideation.
Hypothesis 2: In depressed patients with severe suicidal ideation the rTMS active will reduce impulsive choice behavior (measured as delay discounting) compared with the non-treatment group.
Specific Aim 3. Determine the effect of rTMS on suicidal ideation on depressed patients with severe suicidal ideation.
Hypothesis 3.1: In depressed patients who had recently attempt suicide the rTMS active group will reduce suicidal ideation severity (measured by the Beck Scale for Suicidal Ideation) compared with the non-treatment group.
Hypothesis 3.2: Suicidal ideation in depressed patients who recently attempt suicide will vary in function of delay discounting.
Specific Aim 4. Identification of biomarkers of positive response to rTMS in depressed patients with severe suicidal ideation.
Hypothesis 4: A composite of serum hormonal and inflammatory markers will predict positive response to rTMS in depressed patients with severe suicidal ideation
Suicide has been described as "a permanent solution to a temporary problem" (Buchwald, 2006), reflecting the view that suicide is the result of poor decision making. The strongest biological finding in suicide research is the association with reduced serotonergic neurotransmission, particularly within the ventromedial prefrontal cortex (VMPFC) (Mann, 2003). This deficit in serotonergic neurotransmission is thought to impair cognition, predisposing patients to become more impulsive, rigid in their thinking, and poorer decision makers. Decisions during depressed states are tainted by negative affect and distorted negative cognitions (Martin-Soelch, 2009). However, suicide has been associated with cognitive impairments that go beyond those of depression. Asymptomatic patients with a history of suicide attempts exhibit significant cognitive deficits suggestive of generalized prefrontal cortex (PFC) dysfunction (Raust et al, 2007; Westheide et al, 2008), and corollary disruptions in risk assessment (Martino et al, 2010). Poor inhibition is found in suicide attempters when compared with patients with only suicidal ideation (Burton et al, 2011), and greater cognitive impairments are found in depressed patients with suicidal ideation compared to those without it (Dombrovski et al, 2010). It is possible that cognitive deficits may be specific to suicidal behavior rather than to any comorbid or specific psychiatric diagnosis because this observation holds true for suicidal patients with depression, bipolar disorder, and even temporal lobe epilepsy. However, most of these studies were performed in symptom-free patients, often months or years after the presence of suicidal ideation or behavior. In a previous report (Cáceda et al, 2014) we demonstrated that inability to delay gratification (choosing smaller immediate rewards over larger delayed rewards) is shared by both recent suicide attempters and depressed patients with suicidal ideation. On a follow up assessment, 5-10 days after the suicide attempt, reduction of suicidal ideation and intent was correlated with decreased symptoms of depression and recovery of delayed gratification impairments (Cáceda et al, 2014). These data are congruent with the hypothesis that stressful situations in combination with a biological and psychological predisposition may create a critical climate of overwhelming psychological pain in an individual who chooses an impulsive escapist strategy to terminate his/her own life discounting all future outcomes (Vohs et al, 2002). However, the underlying neural mechanisms remain unknown and therefore not amenable to therapeutic interventions.
TMS is a noninvasive method to cause depolarization or hyperpolarization in the neurons in the brain using electromagnetic induction to induce weak electric currents using a rapidly changing magnetic field. TMS is a novel intervention developed in the field of neurology that has been used in the treatment of patients suffering from migraine, stroke, Parkinson's disease, tinnitus and depression. In healthy subjects, high frequency rTMS over the left DLPFC has been shown to alter impulsive choice behavior (to decrease delay discounting) in healthy individuals and in smokers (Sheffer et al, 2013). On the other hand, a trial of TMS by one of the leaders in the field has shown it to be safe and well tolerated in recent suicide attempters suffering from depression with comorbid post-traumatic stress disorder and traumatic brain injury (George et al, 2014).
Dr. Mennemeier, the director of the Transcranial Magnetic Stimulation Laboratory in the Center for Translational Neuroscience has been using repetitive transcranial magnetic stimulation (rTMS) to understand and treat phantom sound perception in subjects with tinnitus and to examine risky choices and impulsive behaviors using delay discounting in smokers. We propose to replicate a randomized controlled trial of rTMS over 3 days in a sample of well characterized acutely suicidal inpatients.
Our overall hypothesis is that 10 Hertz rTMS of the left dorsolateral prefrontal cortex (DLPFC) will correct impulsive choice behavior deficits found in acutely suicidal patients that in turn will translate into faster resolution of acute suicidal ideation. The current proposal will expand our understanding of the neurobiology of suicidal behavior by examining a potential neurocognitive mechanism of acute suicidality and test the value of rTMS as intervention for acute suicidal behavior. The current proposal will utilize behavioral assessments and rTMS in a randomized controlled trial in a group of adult patients hospitalized: a) following a recent suicide attempt with persistent suicidal ideation, or b) for severe suicidal ideation (n=20). Specifically, we propose:
Specific Aim 1. Determine the safety of repetitive transcranial magnetic stimulation (rTMS) in depressed patients with severe suicidal ideation.
Hypothesis 1: Given studies of rTMS for clinical depression, the investigators predict that rTMS in patients with severe suicidal ideation will be well tolerated and not associated with significant side effects.
Specific Aim 2. Determine the effect of rTMS on delay discounting on depressed patients with severe suicidal ideation.
Hypothesis 2: In depressed patients with severe suicidal ideation the rTMS active will reduce impulsive choice behavior (measured as delay discounting) compared with the non-treatment group.
Specific Aim 3. Determine the effect of rTMS on suicidal ideation on depressed patients with severe suicidal ideation.
Hypothesis 3.1: In depressed patients who had recently attempt suicide the rTMS active group will reduce suicidal ideation severity (measured by the Beck Scale for Suicidal Ideation) compared with the non-treatment group.
Hypothesis 3.2: Suicidal ideation in depressed patients who recently attempt suicide will vary in function of delay discounting.
Specific Aim 4. Identification of biomarkers of positive response to rTMS in depressed patients with severe suicidal ideation.
Hypothesis 4: A composite of serum hormonal and inflammatory markers will predict positive response to rTMS in depressed patients with severe suicidal ideation
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Suicidal Ideation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active rTMS
Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered to the left PFC, defined as a location 6 cm (cm) anterior to the right hand motor thumb area. A research nurse will deliver the treatments. rTMS will be delivered with a figure-eight coil at 120% motor threshold, 10 Hertz (Hz), 5 s (s) train duration, 20 s intertrain interval for 50 min (6000 pulses) 3 times daily for 3 days (total 9 sessions, 54,000 stimuli).
Group Type
ACTIVE_COMPARATOR
repetitive transcranial magnetic stimulation (rTMS)
Intervention Type
DEVICE
A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
Sham rTMS
Parameters for sham Repetitive Transcranial Magnetic Stimulation (rTMS) are identical to those for active stimulation except that aluminum plate blocks the propagation of a magnetic field. The sound and physical sensation is the same as with the active coil while been biologically inactive.
Group Type
SHAM_COMPARATOR
repetitive transcranial magnetic stimulation (rTMS)
Intervention Type
DEVICE
A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
repetitive transcranial magnetic stimulation (rTMS)
A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-60 years, of all races and ethnicities;
* Admitted voluntarily to the adult psychiatric inpatient at PRI;
* Suffering from a current depressive episode
* Reason for hospitalization should be a recent suicide attempt or suicidal ideation
* Current severe suicidal ideation defined by a score \>7 on the Beck Scale for Suicidal Ideation
* Ability to read, write and speak English.
* Admitted voluntarily to the adult psychiatric inpatient at PRI;
* Suffering from a current depressive episode
* Reason for hospitalization should be a recent suicide attempt or suicidal ideation
* Current severe suicidal ideation defined by a score \>7 on the Beck Scale for Suicidal Ideation
* Ability to read, write and speak English.
Exclusion Criteria
* History of dementia, neurovascular or neurodegenerative conditions
* Physical disabilities that prohibit task performance (such as blindness or deafness)
* Choosing to opt out of the research study.
* a personal history or 1st degree relative with history of epilepsy;
* a personal history of head injury, aneurysm, stroke, previous cranial neurosurgery, neurological, or migraines;
* recent use of cocaine or alcohol;
* ferromagnetic metal implants in the head or neck, active or inactive implants(including device leads), deep brain stimulators, cochlear implants or vagus nerve stimulators;
* a pacemaker;
* pregnancy (or the possibility of pregnancy);
* Medications that lower seizure threshold (bupropion or tricyclic antidepressants, such as thorazine, clozapine, amitriptyline, amoxapine, Norpramin, Sinequan, Tofranil, Pamelor, Vivactil, or Surmontil). Other antidepressant and antipsychotic medications have been deemed exhibit a relatively low seizurogenic potential (Pisani et al. 2002).
* Patients taking a medication for weight loss and depression called bupropion (Wellbutrin) they will be excluded because it may increase the likelihood of experiencing a seizure.
* Physical disabilities that prohibit task performance (such as blindness or deafness)
* Choosing to opt out of the research study.
* a personal history or 1st degree relative with history of epilepsy;
* a personal history of head injury, aneurysm, stroke, previous cranial neurosurgery, neurological, or migraines;
* recent use of cocaine or alcohol;
* ferromagnetic metal implants in the head or neck, active or inactive implants(including device leads), deep brain stimulators, cochlear implants or vagus nerve stimulators;
* a pacemaker;
* pregnancy (or the possibility of pregnancy);
* Medications that lower seizure threshold (bupropion or tricyclic antidepressants, such as thorazine, clozapine, amitriptyline, amoxapine, Norpramin, Sinequan, Tofranil, Pamelor, Vivactil, or Surmontil). Other antidepressant and antipsychotic medications have been deemed exhibit a relatively low seizurogenic potential (Pisani et al. 2002).
* Patients taking a medication for weight loss and depression called bupropion (Wellbutrin) they will be excluded because it may increase the likelihood of experiencing a seizure.
Minimum Eligible Age
18 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Arkansas
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pedro L Delgado, MD
Role: PRINCIPAL_INVESTIGATOR
University of Arkansas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Caceda R, Durand D, Cortes E, Prendes-Alvarez S, Moskovciak T, Harvey PD, Nemeroff CB. Impulsive choice and psychological pain in acutely suicidal depressed patients. Psychosom Med. 2014 Jul-Aug;76(6):445-51. doi: 10.1097/PSY.0000000000000075.
Reference Type
BACKGROUND
Heins SE, Crifasi CK. Distinctive injury deaths: the role of environment, policy and measurement across states. Inj Prev. 2016 Aug;22(4):247-52. doi: 10.1136/injuryprev-2015-041833. Epub 2016 Jan 24.
Reference Type
BACKGROUND
Buchwald A. Too soon to say goodbye. 1st ed. New York: Random house; 2006.
Reference Type
BACKGROUND
Mann JJ. Neurobiology of suicidal behaviour. Nat Rev Neurosci. 2003 Oct;4(10):819-28. doi: 10.1038/nrn1220. No abstract available.
Reference Type
BACKGROUND
Martin-Soelch C. Is depression associated with dysfunction of the central reward system? Biochem Soc Trans. 2009 Feb;37(Pt 1):313-7. doi: 10.1042/BST0370313.
Reference Type
BACKGROUND
Westheide J, Quednow BB, Kuhn KU, Hoppe C, Cooper-Mahkorn D, Hawellek B, Eichler P, Maier W, Wagner M. Executive performance of depressed suicide attempters: the role of suicidal ideation. Eur Arch Psychiatry Clin Neurosci. 2008 Oct;258(7):414-21. doi: 10.1007/s00406-008-0811-1. Epub 2008 Mar 11.
Reference Type
BACKGROUND
Raust A, Slama F, Mathieu F, Roy I, Chenu A, Koncke D, Fouques D, Jollant F, Jouvent E, Courtet P, Leboyer M, Bellivier F. Prefrontal cortex dysfunction in patients with suicidal behavior. Psychol Med. 2007 Mar;37(3):411-9. doi: 10.1017/S0033291706009111. Epub 2006 Oct 19.
Reference Type
BACKGROUND
Martino DJ, Strejilevich SA, Torralva T, Manes F. Decision making in euthymic bipolar I and bipolar II disorders. Psychol Med. 2011 Jun;41(6):1319-27. doi: 10.1017/S0033291710001832. Epub 2010 Sep 22.
Reference Type
BACKGROUND
Burton CZ, Vella L, Weller JA, Twamley EW. Differential effects of executive functioning on suicide attempts. J Neuropsychiatry Clin Neurosci. 2011 Spring;23(2):173-9. doi: 10.1176/jnp.23.2.jnp173.
Reference Type
BACKGROUND
Dombrovski AY, Clark L, Siegle GJ, Butters MA, Ichikawa N, Sahakian BJ, Szanto K. Reward/Punishment reversal learning in older suicide attempters. Am J Psychiatry. 2010 Jun;167(6):699-707. doi: 10.1176/appi.ajp.2009.09030407. Epub 2010 Mar 15.
Reference Type
BACKGROUND
Vohs KD, Baumeister R. Escaping the self consumes regulatory resources: a self-regulatory model of suicide. Suicide Science. 2002:33-41.
Reference Type
BACKGROUND
Sheffer CE, Mennemeier M, Landes RD, Bickel WK, Brackman S, Dornhoffer J, Kimbrell T, Brown G. Neuromodulation of delay discounting, the reflection effect, and cigarette consumption. J Subst Abuse Treat. 2013 Aug;45(2):206-14. doi: 10.1016/j.jsat.2013.01.012. Epub 2013 Mar 18.
Reference Type
BACKGROUND
George MS, Raman R, Benedek DM, Pelic CG, Grammer GG, Stokes KT, Schmidt M, Spiegel C, Dealmeida N, Beaver KL, Borckardt JJ, Sun X, Jain S, Stein MB. A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients. Brain Stimul. 2014 May-Jun;7(3):421-31. doi: 10.1016/j.brs.2014.03.006. Epub 2014 Mar 19.
Reference Type
BACKGROUND
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704.
Reference Type
BACKGROUND
HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23(1):56-62. doi: 10.1136/jnnp.23.1.56. No abstract available.
Reference Type
BACKGROUND
Hamilton M. Diagnosis and rating of anxiety. The British journal of psychiatry : the journal of mental science. 1969;3:76-9.
Reference Type
BACKGROUND
Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979 Apr;47(2):343-52. doi: 10.1037//0022-006x.47.2.343. No abstract available.
Reference Type
BACKGROUND
Beck AT. Beck Hopelessness Scale. The Psychological Corporation; 1988.
Reference Type
BACKGROUND
Kirby KN, Petry NM, Bickel WK. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J Exp Psychol Gen. 1999 Mar;128(1):78-87. doi: 10.1037//0096-3445.128.1.78.
Reference Type
BACKGROUND
Owen AM, McMillan KM, Laird AR, Bullmore E. N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. Hum Brain Mapp. 2005 May;25(1):46-59. doi: 10.1002/hbm.20131.
Reference Type
BACKGROUND
Keilp JG, Gorlyn M, Russell M, Oquendo MA, Burke AK, Harkavy-Friedman J, Mann JJ. Neuropsychological function and suicidal behavior: attention control, memory and executive dysfunction in suicide attempt. Psychol Med. 2013 Mar;43(3):539-51. doi: 10.1017/S0033291712001419. Epub 2012 Jul 10.
Reference Type
BACKGROUND
REITAN RM. The relation of the trail making test to organic brain damage. J Consult Psychol. 1955 Oct;19(5):393-4. doi: 10.1037/h0044509. No abstract available.
Reference Type
BACKGROUND
Pridmore S, Fernandes Filho JA, Nahas Z, Liberatos C, George MS. Motor threshold in transcranial magnetic stimulation: a comparison of a neurophysiological method and a visualization of movement method. J ECT. 1998 Mar;14(1):25-7.
Reference Type
BACKGROUND
Mishory A, Molnar C, Koola J, Li X, Kozel FA, Myrick H, Stroud Z, Nahas Z, George MS. The maximum-likelihood strategy for determining transcranial magnetic stimulation motor threshold, using parameter estimation by sequential testing is faster than conventional methods with similar precision. J ECT. 2004 Sep;20(3):160-5. doi: 10.1097/00124509-200409000-00007.
Reference Type
BACKGROUND
Borckardt JJ, Nahas Z, Koola J, George MS. Estimating resting motor thresholds in transcranial magnetic stimulation research and practice: a computer simulation evaluation of best methods. J ECT. 2006 Sep;22(3):169-75. doi: 10.1097/01.yct.0000235923.52741.72.
Reference Type
BACKGROUND
Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008-2039. doi: 10.1016/j.clinph.2009.08.016. Epub 2009 Oct 14.
Reference Type
BACKGROUND
Rossi S, De Capua A, Ulivelli M, Bartalini S, Falzarano V, Filippone G, Passero S. Effects of repetitive transcranial magnetic stimulation on chronic tinnitus: a randomised, crossover, double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):857-63. doi: 10.1136/jnnp.2006.105007. Epub 2007 Feb 21.
Reference Type
BACKGROUND
Langguth B, de Ridder D, Dornhoffer JL, Eichhammer P, Folmer RL, Frank E, Fregni F, Gerloff C, Khedr E, Kleinjung T, Landgrebe M, Lee S, Lefaucheur JP, Londero A, Marcondes R, Moller AR, Pascual-Leone A, Plewnia C, Rossi S, Sanchez T, Sand P, Schlee W, Pysch D, Steffens T, van de Heyning P, Hajak G. Controversy: Does repetitive transcranial magnetic stimulation/ transcranial direct current stimulation show efficacy in treating tinnitus patients? Brain Stimul. 2008 Jul;1(3):192-205. doi: 10.1016/j.brs.2008.06.003. Epub 2008 Jul 1.
Reference Type
BACKGROUND
Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol. 1998 Jan;108(1):1-16. doi: 10.1016/s0168-5597(97)00096-8.
Reference Type
BACKGROUND
Pascual-Leone A, Houser CM, Reese K, Shotland LI, Grafman J, Sato S, Valls-Sole J, Brasil-Neto JP, Wassermann EM, Cohen LG, et al. Safety of rapid-rate transcranial magnetic stimulation in normal volunteers. Electroencephalogr Clin Neurophysiol. 1993 Apr;89(2):120-30. doi: 10.1016/0168-5597(93)90094-6.
Reference Type
BACKGROUND
Grafman J, Pascual-Leone A, Alway D, Nichelli P, Gomez-Tortosa E, Hallett M. Induction of a recall deficit by rapid-rate transcranial magnetic stimulation. Neuroreport. 1994 May 9;5(9):1157-60. doi: 10.1097/00001756-199405000-00034.
Reference Type
BACKGROUND
Flitman SS, Grafman J, Wassermann EM, Cooper V, O'Grady J, Pascual-Leone A, Hallett M. Linguistic processing during repetitive transcranial magnetic stimulation. Neurology. 1998 Jan;50(1):175-81. doi: 10.1212/wnl.50.1.175.
Reference Type
BACKGROUND
Pascual-Leone A, Gates JR, Dhuna A. Induction of speech arrest and counting errors with rapid-rate transcranial magnetic stimulation. Neurology. 1991 May;41(5):697-702. doi: 10.1212/wnl.41.5.697.
Reference Type
BACKGROUND
Counter SA, Borg E, Lofqvist L, Brismar T. Hearing loss from the acoustic artifact of the coil used in extracranial magnetic stimulation. Neurology. 1990 Aug;40(8):1159-62. doi: 10.1212/wnl.40.8.1159.
Reference Type
BACKGROUND
Mennemeier M, Chelette KC, Allen S, Bartel TB, Triggs W, Kimbrell T, Crew J, Munn T, Brown GJ, Dornhoffer J. Variable changes in PET activity before and after rTMS treatment for tinnitus. Laryngoscope. 2011 Apr;121(4):815-22. doi: 10.1002/lary.21425. Epub 2011 Feb 1.
Reference Type
BACKGROUND
Mennemeier M, Chelette KC, Myhill J, Taylor-Cooke P, Bartel T, Triggs W, Kimbrell T, Dornhoffer J. Maintenance repetitive transcranial magnetic stimulation can inhibit the return of tinnitus. Laryngoscope. 2008 Jul;118(7):1228-32. doi: 10.1097/MLG.0b013e318170f8ac.
Reference Type
BACKGROUND
Mennemeier M, Triggs W, Chelette K, Woods A, Kimbrell T, Dornhoffer J. Sham Transcranial Magnetic Stimulation Using Electrical Stimulation of the Scalp. Brain Stimul. 2009 Jul 1;2(3):168-173. doi: 10.1016/j.brs.2009.02.002.
Reference Type
BACKGROUND
Smith JA, Mennemeier M, Bartel T, Chelette KC, Kimbrell T, Triggs W, Dornhoffer JL. Repetitive transcranial magnetic stimulation for tinnitus: a pilot study. Laryngoscope. 2007 Mar;117(3):529-34. doi: 10.1097/MLG.0b013e31802f4154.
Reference Type
BACKGROUND
Roth BJ, Pascual-Leone A, Cohen LG, Hallett M. The heating of metal electrodes during rapid-rate magnetic stimulation: a possible safety hazard. Electroencephalogr Clin Neurophysiol. 1992 Apr;85(2):116-23. doi: 10.1016/0168-5597(92)90077-o.
Reference Type
BACKGROUND
Pascual-Leone A. Handbook of transcranial magnetic stimulation. London New York, NY: Arnold ; Oxford University Press distributor; 2002.
Reference Type
BACKGROUND
Niehaus L, Hoffmann KT, Grosse P, Roricht S, Meyer BU. MRI study of human brain exposed to high-dose repetitive magnetic stimulation of visual cortex. Neurology. 2000 Jan 11;54(1):256-8. doi: 10.1212/wnl.54.1.256.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
203818
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Feasibility and Efficacy of rTMS in Healthy Persons
NCT04074811
WITHDRAWN
NA
Combined TMS and Brief Cognitive Behavioral Therapy to Reduce Suicide
NCT03952468
COMPLETED
NA
fMRI-neuronavigated rTMS for the Treatment of Major Depression Associated With TBI
NCT02980484
TERMINATED
PHASE2
Repetitive Transcranial Magnetic Stimulation (rTMS) in Depression
NCT00920322
TERMINATED
PHASE4
Biomarkers in Depressed Inpatients Receiving Accelerated rTMS
NCT03628573
WITHDRAWN
NA
Neuroimaging Guided and Robot-assisted rTMS for Suicidal Ideation of Depression
NCT04653337
UNKNOWN
PHASE2
Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression & Other Neuropsychiatric Symptoms After Traumatic Brain Injury (TBI)
NCT02367521
COMPLETED
PHASE2/PHASE3
rTMS for Cognitive Rehabilitation After TBI
NCT03642158
COMPLETED
NA
rTMS for Treatment of Depressed Phase of Bipolar Disorder Type II
NCT00447096
WITHDRAWN
PHASE2
Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
NCT02231892
COMPLETED
NA
Can Magnetic Brain Stimulation Help Prevent Relapse in Depression?
NCT02029963
TERMINATED
NA
Brief, High-dose rTMS for Depression
NCT04657432
ACTIVE_NOT_RECRUITING
NA
Repetitive Transcranial Magnetic Stimulation for Treating Depression: A Functional Magnetic Resonance Imaging Study
NCT01162382
TERMINATED
NA
Using rTMS to Treat Depression
NCT05424224
ACTIVE_NOT_RECRUITING
Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression (rTMS)
NCT00190216
TERMINATED
PHASE3
rTMS for Depression
NCT06484413
COMPLETED
Study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Depressed Teens
NCT01502033
COMPLETED
NA
Repetitive Transcranial Magnetic Stimulation for Post-concussion Headaches
NCT06112093
RECRUITING
PHASE1
Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression
NCT01583023
UNKNOWN
PHASE4
Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depressive Disorder
NCT01515215
COMPLETED
NA
50 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease
NCT00977184
COMPLETED
PHASE1/PHASE2
rTMS for PTSD Comorbid With Major Depressive Disorder
NCT02273063
COMPLETED
NA
Repetitive Transcranial Magnetic Stimulation for Dementia
NCT02621424
COMPLETED
NA
Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Depression
NCT01516931
COMPLETED
NA